216 related articles for article (PubMed ID: 18333870)
1. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
[TBL] [Abstract][Full Text] [Related]
2. A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
Jacqmin P; McFadyen L; Wade JR
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):95-106. PubMed ID: 18333871
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Chan PL; Weatherley B; McFadyen L
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):76-85. PubMed ID: 18333869
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
8. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Chan PL; Jacqmin P; Lavielle M; McFadyen L; Weatherley B
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):41-61. PubMed ID: 21088872
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
10. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
[TBL] [Abstract][Full Text] [Related]
11. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
[TBL] [Abstract][Full Text] [Related]
14. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
[TBL] [Abstract][Full Text] [Related]
15. Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.
Brocca-Cofano E; Xu C; Wetzel KS; Cottrell ML; Policicchio BB; Raehtz KD; Ma D; Dunsmore T; Haret-Richter GS; Musaitif K; Keele BF; Kashuba AD; Collman RG; Pandrea I; Apetrei C
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925666
[TBL] [Abstract][Full Text] [Related]
16. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Fang J; Jadhav PR
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):357-68. PubMed ID: 22736302
[TBL] [Abstract][Full Text] [Related]
17. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc.
Carter NJ; Keating GM
Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
